Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alpha blockers

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Alpha blockers. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-002820-20 Sponsor Protocol Number: OZBS62.14078 Start Date*: 2016-02-03
    Sponsor Name:Erasmus MC Dept. Urology
    Full Title: Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis?
    Medical condition: Bladder dysfunction in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10069632 Bladder dysfunction PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012986-67 Sponsor Protocol Number: JJalpha-2009 Start Date*: 2009-11-19
    Sponsor Name:CHU DE POITIERS
    Full Title: Evaluation of the efficacy of Tamsulosine (alpha blockers) compared to phloroglucinol in improving JJ ureteral stent tolerance. A randomized controlled trial.
    Medical condition: Confirmed or potential ureteral obstruction with a uretral stenting indication.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10050307 Ureteral stent insertion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018369-48 Sponsor Protocol Number: CASTIP3 Start Date*: 2011-03-10
    Sponsor Name:Medizinische Universität Wien
    Full Title: Der Einfluss von Adalimumab auf kardiovaskuläre und metabolische Risikofaktoren in der Therapie von Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris im Vergleich zu einer Standardtherap...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004192-37 Sponsor Protocol Number: CRO1749 Start Date*: 2012-04-24
    Sponsor Name:Joint Research Compliance Office, Imperial College
    Full Title: Hellenic Anglo Research into Morning Or Night antihypertensive drug deliverY trial.
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003568-20 Sponsor Protocol Number: RGR Start Date*: 2008-08-08
    Sponsor Name:Prof Alice Stanton
    Full Title: Renin Genotype and Response to Renin Angiotensin System Blockade.
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015653-20 Sponsor Protocol Number: ETN-cohortRA2009 Start Date*: 2010-03-08
    Sponsor Name:
    Full Title: Prospective study on the effects of etanercept treatment in patients with rheumatoid arthritis who are naïve for TNF-alpha blocking therapy and patients who do not respond (anymore) to prior treatm...
    Medical condition: rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005324-41 Sponsor Protocol Number: ACT13739 Start Date*: 2014-10-07
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnose...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-013459-31 Sponsor Protocol Number: AT1001-011 Start Date*: 2009-12-10
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS
    Medical condition: Fabry Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001642-18 Sponsor Protocol Number: WP3 Start Date*: 2019-12-05
    Sponsor Name:Department of Ophthalmology, Rigshospitalet-Glostrup
    Full Title: Effect on the ocular surface when treating glaucoma with eye drops: an investigation of the conjunctival goblet cells
    Medical condition: Open angular glaucoma and ocular hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022636-37 Sponsor Protocol Number: AT1001-012 Start Date*: 2011-01-18
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF AT1001 AND ENZYME REPLACEMENT THERAPY (ERT) IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS, WHO WERE PREVIOU...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Completed) AT (Completed) GR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005035-85 Sponsor Protocol Number: 2012RC14 Start Date*: 2013-05-03
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: A proof of concept study in allergic rhinitis, to evaluate the differential effects of doxazosin between single and chronic dosing on nasal airway calibre
    Medical condition: Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002516-33 Sponsor Protocol Number: NCT01420393 Start Date*: 2015-09-03
    Sponsor Name:University of Ottawa Heart Institute
    Full Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation
    Medical condition: The study is comparing two accepted treatment methods (rhythm control-Catheter ablation with or without anti-arrhythmic drug control of maintaining sinus rhythm versus rate controls with medical th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005170-25 Sponsor Protocol Number: GNT-01-21 Start Date*: 2022-02-10
    Sponsor Name:Genetic S.p.A.
    Full Title: PHASE III MULTICENTER RANDOMIZED TRIAL OF PRESERVATIVE FREE LATANOPROST 50µG/ML VS XALATAN IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
    Medical condition: Patients with Open-Angle Glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084293 Unilateral glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000543-27 Sponsor Protocol Number: 19852012 Start Date*: 2012-04-23
    Sponsor Name:AMC
    Full Title: A Proof of Concept Study to Determine the Local Delivery and Efficacy of Intravenously Injected PEG-Liposomal Prednisolone Sodium Phosphate (Nanocort®) in Atherosclerotic Tissue in Subjects with Pe...
    Medical condition: Vessel wall inflammation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003135-30 Sponsor Protocol Number: URO-901-3005 Start Date*: 2019-12-12
    Sponsor Name:Urovant Sciences GmbH
    Full Title: A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacolog...
    Medical condition: Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) ES (Ongoing) HU (Completed) PT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004422-17 Sponsor Protocol Number: ANDRO-AOUC-2014-1 Start Date*: 2015-04-14
    Sponsor Name:UNIVERSITY OF FLORENCE
    Full Title: Double-blinded placebo-controlled study on men with lower urinary tract symptoms secondary to prostatic hyperplasia (LUTS-BPH) to assess changes in pressure flow study (PFS) and in molecular profil...
    Medical condition: lower urinary tract symptoms/benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038359 - Renal and urinary disorders 10071289 Lower urinary tract symptoms PT
    17.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004452-13 Sponsor Protocol Number: A6121127 Start Date*: 2005-12-16
    Sponsor Name:Pfizer Inc.
    Full Title: A Randomized, Double Blind, Placebo Controlled Detrol La "Add-On" To Alpha-Blocker Study in men with persistent Overactive Bladder symptoms of urinary frequency and urgency with/without urgency inc...
    Medical condition: Overactive Bladder in Men
    Disease: Version SOC Term Classification Code Term Level
    8.0 10020853 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed) ES (Completed) DK (Completed) GB (Completed) SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004321-15 Sponsor Protocol Number: H6D-MC-LVHK(b) Start Date*: 2007-12-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign P...
    Medical condition: Effects on urodynamic parameters in men with benign prostatic hyperplasia (also referred to as BPH-LUTS [lower urinary tract symptoms]) with and without urodynamic evidence of bladder outlet obstru...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002841-21 Sponsor Protocol Number: H6D-MC-LVHJ(a) Start Date*: 2008-10-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004609-85 Sponsor Protocol Number: UV2005/01 Start Date*: 2008-03-18
    Sponsor Name:OM Pharma SA
    Full Title: Multicentre, randomised, double-blind, placebo-controlled clinical study to assess the efficacy and safety of UroVaxom in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS)
    Medical condition: Chronic prostatitis and chronic pelvic pain syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10064189 Chronic pelvic pain syndrome LLT
    14.1 10038604 - Reproductive system and breast disorders 10009109 Chronic prostatitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) AT (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 22 16:25:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA